GLUT1 Protein Expression Correlates with Unfavourable Histologic Category and High Risk in Patients with Neuroblastic Tumours

Overview

Journal Virchows Arch

Specialties Cell Biology
Molecular Biology
Pathology

Date 2013 Jan 12

PMID 23307190

Citations 16

Authors

Pramila Ramani

Alison Headford

Margaret T May

Affiliations

Soon will be listed here.

Abstract

GLUT1 is a hypoxia-induced gene that has many biologically important functions, and the overexpression of the GLUT1 protein correlates with poor prognosis in several adult cancers. The clinical significance of the GLUT1 protein in peripheral neuroblastic tumours (NTs) has not been comprehensively documented. In the present retrospective study, immunohistochemical analyses revealed the presence of GLUT1 in 44/96 (46 %) NTs. Membranous GLUT1 was present in neuroblasts of 44/87 neuroblastomas (NBs) and nodular ganglioneuroblastomas (nGNBs) but was absent in ganglion cells. The presence of GLUT1 was significantly increased in NBs and nGNBs compared with maturing ganglioneuromas and intermixed ganglioneuroblastomas (P < 0.001). The proportion of NBs and nGNBs expressing GLUT1 was significantly increased in the high-risk and low/intermediate-risk groups compared with the very-low-risk group (P = 0.022) and the unfavourable compared with the favourable pathology prognostic group (P = 0.027). In the Cox regression analyses, GLUT1 expression indicated a worse overall survival (OS; hazard rate ratio (HR) 2.29, P = 0.053) and event-free survival (EFS; HR 1.68, P = 0.181) which was not attenuated by adjustment for the mitosis-karyorrhexis index and MYCN amplification (OS: adjusted HR 2.44, P = 0.053 and EFS: adjusted HR 1.63, P = 0.244). This indicated that GLUT1 protein expression was independent of mitosis-karyorrhexis index and MYCN amplification as a prognostic factor. Our data may have clinical significance because GLUT1 was also present in a higher proportion of high-risk NTs.

Citing Articles

GAPDH in neuroblastoma: Functions in metabolism and survival.

Cornett K, Puderbaugh A, Back O, Craven R Front Oncol. 2022; 12:979683.

PMID: 36267982 PMC: 9577191. DOI: 10.3389/fonc.2022.979683.

MFSD4A inhibits the malignant progression of nasopharyngeal carcinoma by targeting EPHA2.

Yang H, Qin G, Luo Z, Kong X, Gan C, Zhang R Cell Death Dis. 2022; 13(4):332.

PMID: 35410462 PMC: 9001682. DOI: 10.1038/s41419-022-04793-x.

LINC00839 Regulates Proliferation, Migration, Invasion, Apoptosis and Glycolysis in Neuroblastoma Cells Through miR-338-3p/GLUT1 Axis.

Yang L, Pei L, Yi J Neuropsychiatr Dis Treat. 2021; 17:2027-2040.

PMID: 34188473 PMC: 8232867. DOI: 10.2147/NDT.S309467.

High Expression of Solute Carrier Family 2 Member 1 (SLC2A1) in Cancer Cells Is an Independent Unfavorable Prognostic Factor in Pediatric Malignant Peripheral Nerve Sheath Tumor.

Krawczyk M, Kunc M, Styczewska M, Gabrych A, Karpinsky G, Izycka-Swieszewska E Diagnostics (Basel). 2021; 11(4).

PMID: 33810575 PMC: 8065586. DOI: 10.3390/diagnostics11040598.

Potential Role of Glucose Transporter-1 Expression in Gastric Cancer: A Meta-Analysis and Systematic Review.

Tao J, Zhang Y, Wang T Iran J Public Health. 2021; 49(11):2044-2053.

PMID: 33708725 PMC: 7917512. DOI: 10.18502/ijph.v49i11.4719.

References

Brand K . Aerobic glycolysis by proliferating cells: protection against oxidative stress at the expense of energy yield. J Bioenerg Biomembr. 1997; 29(4):355-64. DOI: 10.1023/a:1022498714522. View

Monclair T, Brodeur G, Ambros P, Brisse H, Cecchetto G, Holmes K . The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):298-303. PMC: 2650389. DOI: 10.1200/JCO.2008.16.6876. View

Cohn S, Pearson A, London W, Monclair T, Ambros P, Brodeur G . The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):289-97. PMC: 2650388. DOI: 10.1200/JCO.2008.16.6785. View

Janoueix-Lerosey I, Schleiermacher G, Delattre O . Molecular pathogenesis of peripheral neuroblastic tumors. Oncogene. 2010; 29(11):1566-79. DOI: 10.1038/onc.2009.518. View

Dungwa J, Hunt L, Ramani P . HIF-1α up-regulation is associated with adverse clinicopathological and biological factors in neuroblastomas. Histopathology. 2012; 61(3):417-27. DOI: 10.1111/j.1365-2559.2012.04227.x. View

Shimada H, Umehara S, Monobe Y, Hachitanda Y, Nakagawa A, Goto S . International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer. 2001; 92(9):2451-61. DOI: 10.1002/1097-0142(20011101)92:9<2451::aid-cncr1595>3.0.co;2-s. View

Ljungkvist A, Bussink J, Rijken P, Raleigh J, Denekamp J, van der Kogel A . Changes in tumor hypoxia measured with a double hypoxic marker technique. Int J Radiat Oncol Biol Phys. 2000; 48(5):1529-38. DOI: 10.1016/s0360-3016(00)00787-2. View

Dungwa J, Hunt L, Ramani P . Carbonic anhydrase IX up-regulation is associated with adverse clinicopathologic and biologic factors in neuroblastomas. Hum Pathol. 2012; 43(10):1651-60. DOI: 10.1016/j.humpath.2011.12.006. View

Hu C, Wang L, Chodosh L, Keith B, Simon M . Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol. 2003; 23(24):9361-74. PMC: 309606. DOI: 10.1128/MCB.23.24.9361-9374.2003. View

10.

Jubb A, Buffa F, Harris A . Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis. J Cell Mol Med. 2009; 14(1-2):18-29. PMC: 3837600. DOI: 10.1111/j.1582-4934.2009.00944.x. View

11.

Brodeur G, Pritchard J, Berthold F, Carlsen N, Castel V, Castelberry R . Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993; 11(8):1466-77. DOI: 10.1200/JCO.1993.11.8.1466. View

12.

Semenza G . Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci. 2012; 33(4):207-14. PMC: 3437546. DOI: 10.1016/j.tips.2012.01.005. View

13.

Rojas Ayala F, Rocha R, Carvalho K, Carvalho A, da Cunha I, Lourenco S . GLUT1 and GLUT3 as potential prognostic markers for Oral Squamous Cell Carcinoma. Molecules. 2010; 15(4):2374-87. PMC: 6257354. DOI: 10.3390/molecules15042374. View

14.

Vaupel P, Mayer A . Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007; 26(2):225-39. DOI: 10.1007/s10555-007-9055-1. View

15.

Bardos J, Ashcroft M . Negative and positive regulation of HIF-1: a complex network. Biochim Biophys Acta. 2005; 1755(2):107-20. DOI: 10.1016/j.bbcan.2005.05.001. View

16.

Ito S, Fukusato T, Nemoto T, Sekihara H, Seyama Y, Kubota S . Coexpression of glucose transporter 1 and matrix metalloproteinase-2 in human cancers. J Natl Cancer Inst. 2002; 94(14):1080-91. DOI: 10.1093/jnci/94.14.1080. View

17.

Mendez L, Manci N, Cantuaria G, Gomez-Marin O, Penalver M, Braunschweiger P . Expression of glucose transporter-1 in cervical cancer and its precursors. Gynecol Oncol. 2002; 86(2):138-43. DOI: 10.1006/gyno.2002.6745. View

18.

Shimada H, Ambros I, Dehner L, Hata J, JOSHI V, Roald B . The International Neuroblastoma Pathology Classification (the Shimada system). Cancer. 1999; 86(2):364-72. View

19.

Porporato P, Dhup S, Dadhich R, Copetti T, Sonveaux P . Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front Pharmacol. 2011; 2:49. PMC: 3161244. DOI: 10.3389/fphar.2011.00049. View

20.

Maris J, Hogarty M, Bagatell R, Cohn S . Neuroblastoma. Lancet. 2007; 369(9579):2106-20. DOI: 10.1016/S0140-6736(07)60983-0. View